MDT

89.67

-0.33%↓

VEEV

282.88

+2.55%↑

A

120.56

-2.22%↓

WBA

11.48

-0.26%↓

HQY

96.75

+2.44%↑

MDT

89.67

-0.33%↓

VEEV

282.88

+2.55%↑

A

120.56

-2.22%↓

WBA

11.48

-0.26%↓

HQY

96.75

+2.44%↑

MDT

89.67

-0.33%↓

VEEV

282.88

+2.55%↑

A

120.56

-2.22%↓

WBA

11.48

-0.26%↓

HQY

96.75

+2.44%↑

MDT

89.67

-0.33%↓

VEEV

282.88

+2.55%↑

A

120.56

-2.22%↓

WBA

11.48

-0.26%↓

HQY

96.75

+2.44%↑

MDT

89.67

-0.33%↓

VEEV

282.88

+2.55%↑

A

120.56

-2.22%↓

WBA

11.48

-0.26%↓

HQY

96.75

+2.44%↑

Search

Corvus Pharmaceuticals Inc

Open

4.23 2.42

Overview

Share price change

24h

Current

Min

4.08

Max

4.3

Key metrics

By Trading Economics

Income

27M

15M

Employees

31

EBITDA

-1.8M

-9.9M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+214.01% upside

Dividends

By Dow Jones

Next Earnings

5 sie 2025

Market Stats

By TradingEconomics

Market Cap

24M

301M

Previous open

1.81

Previous close

4.23

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Corvus Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 lip 2025, 22:19 UTC

Acquisitions, Mergers, Takeovers

FCC Approves U.S. Cellular Sale to T-Mobile

11 lip 2025, 17:28 UTC

Major Market Movers

SharpLink Gaming Gains on Ethereum Purchase

11 lip 2025, 16:57 UTC

Earnings

BASF Cuts Outlook on Global Economy Uncertainty

13 lip 2025, 23:54 UTC

Market Talk

Oil Edges Higher Amid Supply Disruption Worries -- Market Talk

13 lip 2025, 23:49 UTC

Market Talk

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

13 lip 2025, 23:49 UTC

Market Talk

Global Equities Roundup: Market Talk

13 lip 2025, 23:40 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

13 lip 2025, 23:40 UTC

Market Talk

Gold Advances Amid Rising Trade Tensions -- Market Talk

13 lip 2025, 23:39 UTC

Market Talk

China's Growth Momentum Likely Slowed in 2Q -- Market Talk

13 lip 2025, 23:16 UTC

Earnings

China Shenhua Energy 1H 2024 Net Was CNY32.8B>1088.HK

13 lip 2025, 23:16 UTC

Earnings

China Shenhua Energy: Drop in Coal Prices Weighed on Results >1088.HK

13 lip 2025, 23:16 UTC

Earnings

China Shenhua Energy Sees 1H Net CNY25.6B-Net CNY27.6B >1088.HK

13 lip 2025, 23:13 UTC

Market Talk

Global Equities Roundup: Market Talk

13 lip 2025, 23:13 UTC

Market Talk

Ryman Healthcare Could Be Turning a Corner -- Market Talk

13 lip 2025, 11:00 UTC

Acquisitions, Mergers, Takeovers

The Private-Equity Maneuver Allowing More Investors to Cash Out -- WSJ

12 lip 2025, 02:24 UTC

Acquisitions, Mergers, Takeovers

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- Update

12 lip 2025, 02:05 UTC

Acquisitions, Mergers, Takeovers

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- WSJ

12 lip 2025, 02:05 UTC

Acquisitions, Mergers, Takeovers

Google to Hire Windsurf CEO and Other Employees, Company Says -- WSJ

12 lip 2025, 02:05 UTC

Acquisitions, Mergers, Takeovers

Google to Pay About $2.4 Billion in Deal to License Tech of AI Coding Startup, Sources Say -- WSJ

11 lip 2025, 21:45 UTC

Market Talk

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 lip 2025, 19:46 UTC

Acquisitions, Mergers, Takeovers

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 lip 2025, 19:45 UTC

Market Talk

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 lip 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 lip 2025, 18:18 UTC

Market Talk

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 lip 2025, 17:35 UTC

Market Talk

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 lip 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 lip 2025, 16:53 UTC

Market Talk

Crude Futures Add to Early Gains -- Market Talk

11 lip 2025, 16:42 UTC

Earnings

BASF Cuts Outlook on Global Economic Uncertainty

11 lip 2025, 16:08 UTC

Market Talk

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 lip 2025, 16:05 UTC

Earnings

BASF Will Publish Half-Year Results on July 30

Peer Comparison

Price change

Corvus Pharmaceuticals Inc Forecast

Price Target

By TipRanks

214.01% upside

12 Months Forecast

Average 13 USD  214.01%

High 17 USD

Low 11 USD

Based on 4 Wall Street analysts offering 12 month price targets forCorvus Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

3.165 / 3.5827Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.